Omeros prices $22M offering, discloses advanced partnership talks, narsoplimab PDUFA now Dec 2025

OMEROS CORP

Sold 5,365,853 shares at $4.10 each to Polar Asset Management; net proceeds ~$20.3M; expected close July 28.
Narsoplimab BLA PDUFA date extended from Sep 25, 2025 to Dec 26, 2025; labeling discussions planned by Oct 2025.
Advanced partnership discussion: potential multi-billion transaction value excl. royalties; upfront would repay $67.1M term loan and $17.1M notes.
Cash and equivalents $26.0M as of July 18; 61.8M shares outstanding.
PDE7 inhibitor program: preclinical studies for cocaine use disorder completed; FDA requests more preclinical info.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.